UB Paderborn / Katalog / Suche / in CDI

Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient‐derived xenograft (PDX) models

The Prostate, 2018-12, Vol.78 (16), p.1262-1282

2018

Volltextzugriff (PDF)

Reagents for Astatination of Biomolecules. 5. Evaluation of Hydrazone Linkers in 211At- and 125I-Labeled closo-Decaborate(2-) Conjugates of Fab′ as a Means of Decreasing Kidney Retention

Bioconjugate chemistry, 2011-05, Vol.22 (6), p.1089-1102

2011

Volltextzugriff (PDF)

Transforming Growth Factor-β–Stimulated Clone-22 Is an Androgen-Regulated Gene That Enhances Apoptosis in Prostate Cancer following Insulin-Like Growth Factor-I Receptor Inhibition

Clinical cancer research, 2009-12, Vol.15 (24), p.7634-7641

2009

Volltextzugriff (PDF)

Plasma Fatty Acids as Surrogate for Prostate Levels

Nutrition and cancer, 2018-01, Vol.70 (1), p.45-50

2018

Volltextzugriff (PDF)

Metastatic Progression of Prostate Cancer and E-Cadherin

The American journal of pathology, 2011-07, Vol.179 (1), p.400-410

2011

Volltextzugriff (PDF)

Tumor cell dormancy: An NCI workshop report

Cancer biology & therapy, 2007-09, Vol.6 (9), p.1492-1500

2007

Volltextzugriff (PDF)

Inhibition of Androgen-independent Growth of Prostate Cancer Xenografts by 17β-Estradiol

Clinical cancer research, 2002-04, Vol.8 (4), p.1003-1007

2002

Volltextzugriff (PDF)

EFFECT OF ANDROGEN DEPRIVATION THERAPY ON DISSEMINATED TUMOR CELLS IN MEN WITH PROSTATE CANCER

The Journal of urology, 2009, Vol.181 (4), p.775-775

2009

Volltextzugriff (PDF)

Prostate Cancer-Associated Membrane Type 1-Matrix Metalloproteinase

The American journal of pathology, 2007, Vol.170 (6), p.2100-2111

2007

Volltextzugriff (PDF)

Are Circulating Phospholipid Fatty Acids a Reasonable Surrogate for Target Tissue Levels In The Prostate?

Nutrition and cancer, 2017-12, Vol.70 (1), p.45-50

2017

Volltextzugriff (PDF)

Targeting FOXAI-mediated repression of TGF-[beta] signaling suppresses castration-resistant prostate cancer progression

The Journal of clinical investigation, 2019-02, Vol.129 (2), p.569

2019

Volltextzugriff (PDF)

Editorial Comment

The Journal of urology, 2008-06, Vol.179 (6), p.2191-2191

Vessella, Robert L.

2008

Volltextzugriff (PDF)

Editorial Comment

The Journal of urology, 2008, Vol.179 (6), p.2191-2191

Vessella, Robert L

2008

Volltextzugriff (PDF)

Abstract 5205: CCND1 is a miR-193b target in prostate cancer

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.5205-5205

2014

Volltextzugriff (PDF)

Abstract 1685: In vivo efficacy of PSMA ADC in combination with enzalutamide in castration-resistant prostate cancer

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.1685-1685

2015

Volltextzugriff (PDF)

Abstract IA21: AR is ablated: Now what? Targeting the double-negative phenotype

Cancer research (Chicago, Ill.), 2018-08, Vol.78 (16_Supplement), p.IA21-IA21

2018

Volltextzugriff (PDF)

Abstract 735: Evaluation of cabozantinib in combination with abiraterone, enzalutamide or docetaxel in a castration-resistant prostate cancer xenograft in vivo

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.735-735

2014

Volltextzugriff (PDF)

Abstract 737: Assessment of cabozantinib activity in diverse prostate cancer xenograft models

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.737-737

2014

Volltextzugriff (PDF)

Abstract 1214: Preclinical models of prostate cancer: New patient-derived xenografts for preclinical studies and evaluation of prostate cancer biology

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.1214-1214

2014

Volltextzugriff (PDF)

GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models

Clinical cancer research, 2016-07, p.clincanres.0137.2016

2016

Volltextzugriff (PDF)

Abstract A109: Radium-223 dichloride inhibits tumor growth and tumor-induced bone growth in osteoblastic prostate cancer models

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.A109-A109

2015

Volltextzugriff (PDF)

LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics: Prostate Cancer PDXs: LuCaP Series

The Prostate, 2017-05, Vol.77 (6), p.654-671

2017

Volltextzugriff (PDF)

Abstract 1718: The importance of clinically relevant rapid autopsy specimens and LuCaP patient-derived xenograft models to interrogate the heterogeneous and evolving treatment resistance of castration-resistant prostate cancer

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.1718-1718

2015

Volltextzugriff (PDF)

Abstract 4313: Abiraterone acetate (AA) treatment of prostate cancer patient-derived xenografts (PDX) demonstrates heterogeneity of responses and identifies potential biomarkers of adaptive resistance

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.4313-4313

2015

Volltextzugriff (PDF)

Abstract 3447: Radium-223 dichloride exhibits dual mode-of-action inhibiting both tumor and tumor-induced bone growth in two osteoblastic prostate cancer models

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.3447-3447

2015

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient‐derived xenograft (PDX) models

Reagents for Astatination of Biomolecules. 5. Evaluation of Hydrazone Linkers in 211At- and 125I-Labeled closo-Decaborate(2-) Conjugates of Fab′ as a Means of Decreasing Kidney Retention

Transforming Growth Factor-β–Stimulated Clone-22 Is an Androgen-Regulated Gene That Enhances Apoptosis in Prostate Cancer following Insulin-Like Growth Factor-I Receptor Inhibition

Plasma Fatty Acids as Surrogate for Prostate Levels

Metastatic Progression of Prostate Cancer and E-Cadherin

Tumor cell dormancy: An NCI workshop report

Inhibition of Androgen-independent Growth of Prostate Cancer Xenografts by 17β-Estradiol

EFFECT OF ANDROGEN DEPRIVATION THERAPY ON DISSEMINATED TUMOR CELLS IN MEN WITH PROSTATE CANCER

Prostate Cancer-Associated Membrane Type 1-Matrix Metalloproteinase

Are Circulating Phospholipid Fatty Acids a Reasonable Surrogate for Target Tissue Levels In The Prostate?

Targeting FOXAI-mediated repression of TGF-[beta] signaling suppresses castration-resistant prostate cancer progression

Editorial Comment

Editorial Comment

Abstract 5205: CCND1 is a miR-193b target in prostate cancer

Abstract 1685: In vivo efficacy of PSMA ADC in combination with enzalutamide in castration-resistant prostate cancer

Abstract IA21: AR is ablated: Now what? Targeting the double-negative phenotype

Abstract 735: Evaluation of cabozantinib in combination with abiraterone, enzalutamide or docetaxel in a castration-resistant prostate cancer xenograft in vivo

Abstract 737: Assessment of cabozantinib activity in diverse prostate cancer xenograft models

Abstract 1214: Preclinical models of prostate cancer: New patient-derived xenografts for preclinical studies and evaluation of prostate cancer biology

GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models

Abstract A109: Radium-223 dichloride inhibits tumor growth and tumor-induced bone growth in osteoblastic prostate cancer models

LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics: Prostate Cancer PDXs: LuCaP Series

Abstract 1718: The importance of clinically relevant rapid autopsy specimens and LuCaP patient-derived xenograft models to interrogate the heterogeneous and evolving treatment resistance of castration-resistant prostate cancer

Abstract 4313: Abiraterone acetate (AA) treatment of prostate cancer patient-derived xenografts (PDX) demonstrates heterogeneity of responses and identifies potential biomarkers of adaptive resistance

Abstract 3447: Radium-223 dichloride exhibits dual mode-of-action inhibiting both tumor and tumor-induced bone growth in two osteoblastic prostate cancer models

Aktive Filter

Suchergebnisse filtern